Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Home
Chimeric Therapeutics Limited Temp
CHM CORE-NK Phase 1B clinical trial achieves 60% CR/CRi
Business
3d ago
3 min read

CHM CORE-NK Phase 1B clinical trial achieves 60% CR/CRi

news images

Chimeric Therapeutics Limited Temp has released a press release.

View Attachment